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See EDITORIAL page 279 total expenditure. Our main strategic goals are to broaden the research base for global health research by increasing the number of individual researchers, and institutions and systems within which they can ourish; to support research that will bene t health -and the opportunity to make a di erence is nowhere clearer than in resource-poor settings; to support networks and partnerships focused on the problems of low-and middle-income countries where there are shared aims and a synergy of expertise.
It is people who conduct scientific research and we aim to identify and fund those scientists who are asking the highest quality research questions wherever they may be in the world.
Several of the Millennium Development Goals focus on health, and in many cases the most e ective way to prevent morbidity and mortality is to vaccinate susceptible populations. Vaccinology and research into vaccine development and deployment are, therefore, important components of our science-funding portfolio, and we use multiple mechanisms in exible ways to support research in these elds.
A FUNDERS APPROACH TO

VACCINOLOGY
e path to successful vaccine delivery can be considered in a step-wise manner (see Figure 1 ). It starts with basic research to understand e ective immune mechanisms and to develop candidate vaccine constructs, moves through pre-clinical and clinical trials and onto health systems and health policy
ere is currently an increased interest in global health among politicians and policy makers, funding agencies both governmental and philanthropic, and in civil societies around the world. e focus of " Research for Health, " as articulated at the recent Global Ministerial Forum in Bamako, 1 highlights the relevance of research to improve well-being of human populations in low-and middle-income countries. e recent G-Finder report has documented the extent of funding on neglected disease research and development 2 and indicates that though such research is conducted by a wide variety of organizations including those in academia, public institutions, and private companies, it is funded by a relatively small number of organizations with increasing proportions being provided by private and philanthropic organizations rather than governments, even those of wealthy countries. e report notes the tendency to focus on developing new drugs and vaccines for a small number of diseases rather than on the wider agenda of diagnostics, platform technologies, and developing country-speci c products needed for many high-burden, highmortality diseases.
Using the Wellcome Trust as an example of a major medical research charity, we discuss how we have responded to these recent changes in circumstance and attitude toward global health. Although we have had a long-term interest in funding of tropical medicine research, starting with an award to Henry Foy in 1938 to study malaria control in Greece, today we fund thousands of researchers in dozens of countries around the world and have expanded the proportion of our international funding to around 15 % of Science funding in low-and middle-income countries: the example of vaccine research
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There has been a recent increase in funding sources and overall commitment to tackle global health issues and reduce morbidity and mortality. The Wellcome Trust, the UK ' s largest charity, has a long track record of funding research in global health and has developed a new research strategy to tackle these issues. Here, we describe the Wellcome Trust ' s approach to funding researchers in low-and middle-income countries with a focus on how our funding portfolio supports vaccine delivery and development, with specific reference to mucosal immunity.
nature publishing group COMMENTARIES research into delivery in populations and nally end-game issues relating to elimination and eradication. Successful vaccine development and delivery will require commitment to networks and partnerships from many players including academia, industry, public -private partnerships, government, policy makers, as well as donor and funding agencies. We have examined the steps involved in vaccine delivery and particularly focus on how to overcome the gaps and hurdles that occur along each step of the developmental pathway.
e basic scienti c challenges to vaccine development include improving molecular understanding of target antigens and developing related diagnostic tools, improving understanding of the various arms of the immune system in protection, and understanding how to elicit broad and persistent immune responses. Historically most successes in immunization have been achieved through the induction of protective antibodies, whereas a major challenge facing vaccinology today is the induction of broad-based persistent T-cell immunity and memory B cells, through CD4 + and CD8 + cell responses. Mucosal surfaces are major portals of entry for important pathogens, such as infections of the lower respiratory tract including tuberculosis, diarrheal diseases, HIV, and other sexually transmitted infections. Mucosal infections are particular problems in low-and middle-income countries where sanitation and health education are lacking, and as such represent a major target for vaccine development. However, a better understanding of the mucosal immune system is required to facilitate further mucosal vaccine development. Our understanding is limited, and necessitates research in developing countries to ensure appreciation of real-world issues such as co-existing malnutrition and concurrent infections, especially chronic infections causing in ammation and altered immune responses, such as helminths and HIV infections. Oral immunization using living organisms to stimulate mucosal responses have been used for some time 
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• Academia and Industry • Funding Agencies e.g. Wellcome Trust, Bill and Melinda Gates Foundation Challenges for testing candidates in preclinical studies include development of potent adjuvants, systematic methods for identi cation of correlates of protection, and identi cation of surrogate markers of e cacy and toxicity. e lack of surrogate means of testing vaccine e cacy and limited knowledge of correlates of protection limits the early assessment of many vaccines, including those for HIV, malaria, and TB. is contributes to ine cient and costly vaccine development. ere are currently very few adjuvants that are licensed for use in humans, especially for mucosal vaccines, and access to these is limited because of commercial sensitivities and a lack of formulation data. As we move forward, there may also be a need for tailor-made adjuvants as the trend develops toward subunit vaccines that have o en limited immunogenicity. Fortunately, there has been much interest in this area over the past few years particularly to increase access through partnerships between academia and industry. We recently issued a targeted call for research proposals in this eld.
Clinical vaccine trials in developing countries are limited by the lack of infrastructure for eld trial sites, the number of trained investigators in low-and middle-income countries, and market failure and political inertia worldwide. We have highlighted the need to strengthen capacity for health research in low-and middle-income countries, particularly those in Africa, 3 and the Wellcome Trust has recently developed initiatives to increase research capacity at individual, institutional, and systems levels in Africa through the Health Research Capacity Strengthening Initiative, 4 -6 the African Institutions Initiative, 7 and also through a new partnership with the Indian Government aiming to fund around 70 new fellowships for Indian scientists each year. 8 Vaccines may perform di erently in developing country populations where many diseases are endemic and disease exposure and earlier immunity varies; therefore, it is imperative that clinical trials are conducted in those populations that stand to gain the most from their implementation. A recent example being for the newly developed rotavirus vaccines. e Wellcome Trust does fund a small number of clinical trials, especially, in developing countries and where there is a limited commercial drive for development, through both our Technology Transfer Divisions and the Science Funding Populations and Public Health Funding Committee.
Once vaccines have been evaluated, there are major challenges for e ective delivery to target populations. Epidemiological surveillance data are required to guide policy makers in making rational decisions about vaccine deployment. is requires new diagnostic and surveillance tools and strengthening of infrastructure and healthcare systems. There is some appreciation of the global burden and importance of the major tropical diseases, HIV, TB, and malaria 9,10 but for many diseases, even those with high mortality and morbidity, for example cholera and typhoid, there is gross under-reporting and under-funding. Even when vaccines are deployed, supply can be insu cient, vaccine manufacturers may be too few and regulatory pressures render production increasingly di cult. e Wellcome Trust works with the World Health Organization and other policy-making and funding bodies to plan for public health threats such as influenza pandemics by documenting existing research activities and mapping out important research priorities for the future, and to support cost-bene t analyses to inform governments of the practicalities of introducing a vaccine.
e nal stage represents end-game concerns and preparing for elimination and eradication. Establishing if an infectious disease has been eliminated is no easy task, especially when infection can be asymptomatic, as is the case for 90 % of poliovirus infections. Certi ed eradication relies on excellent surveillance and laboratory diagnosis. Polio end-game issues include when to stop vaccinating, when to move from live-attenuated oral polio vaccine (which can cause vaccinederived polio) to more costly inactivated injectable polio vaccine, and the continuing need for surveillance. As diseases decline and pro les are reduced, the need for control strategies becomes less evident to policy makers and the need for public engagement and education increases.
CONCLUSION
The Wellcome Trust over the 10 years between 1995 and 2005, committed over £ 73 million to the area of vaccinology, supporting a wide range of science from basic research through clinical trials and public health research through multiple mechanisms of support. Of this commitment, approximately 30 % of grants involved either direct or indirect funding to low-or middle-income countries. We remain committed to research for health that will improve the use of vaccines available today and identify the new vaccines that will be required in the future.
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